EV-Pem
EV-Pem improved progression-free and overall survival compared with chemotherapy in EV-302. EV-Pem is not cost-effective at the standard UK willingness-to-pay threshold of £30,000 per QALY. EV-Pem requires substantial price reductions to m…
1 sources - 4 claims
EV-Pem improved progression-free and overall survival compared with chemotherapy in EV-302. EV-Pem is not cost-effective at the standard UK willingness-to-pay threshold of £30,000 per QALY. EV-Pem requires substantial price reductions to meet NICE cost-effectiveness standards. EV-Pem is a first-line treatment combination for locally advanced or metastatic urothelial carcinoma based on the EV-302 trial.